Key result
Combined therapy with small doses of losartan and enalapril reduced proteinuria by 65.96%, which was significantly more pronounced than losartan monotherapy (25.35%; p=0.009).
Why the study?
Does low-dose losartan, enalapril, or their combination reduce proteinuria in patients with primary glomerulonephritis?
Population
51 patients with biopsy proven chronic glomerulonephritis with normal or slightly declined kidney function.
Comparison
Losartan 25 mg, enalapril 10 mg, or a… vs Active comparators.
Design
RCT, randomized
Follow-up
3 months
Authors
Loading...
Low-dose losartan-enalapril combination yields greater proteinuria reduction than monotherapy in primary glomerulonephritis; extends dual RAAS blockade evidence while warranting GFR monitoring.
RCT (n=51)
randomized
Does low-dose losartan, enalapril, or their combination reduce proteinuria in patients with primary glomerulonephritis?
Absolute Event Rate: 65.96% vs 25.35%
p-value: p=0.009
In patients with primary glomerulonephritis, combining low doses of losartan and enalapril provides greater antiproteinuric effects than monotherapy, though enalapril may carry a higher risk of acute GFR decline.
Tylicki et al. (2002) conducted an RCT in chronic glomerulonephritis (n=51). Combination of losartan and enalapril vs. losartan 25 mg or enalapril 10 mg monotherapy was evaluated on reduction of proteinuria (p=0.009). Combined therapy with small doses of losartan and enalapril reduced proteinuria by 65.96%, which was significantly more pronounced than losartan monotherapy (25.35%; p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: